Cortexyme, Inc. (NASDAQ:CRTX - Get Free Report)'s share price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.37 and traded as high as $1.89. Cortexyme shares last traded at $1.78, with a volume of 310,693 shares trading hands.
Cortexyme Trading Up 3.3%
The business has a fifty day simple moving average of $1.31 and a 200 day simple moving average of $1.37. The stock has a market capitalization of $56.99 million, a P/E ratio of -0.64 and a beta of 1.40.
Cortexyme Company Profile
(
Get Free Report)
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Stories
Before you consider Cortexyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cortexyme wasn't on the list.
While Cortexyme currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access